One of the most common tumor-related signaling pathways, the PI3K/AKT/mTOR signaling pathway, exhibits aberrant hyperactivation in a range of tumor forms, including breast cancer, colorectal cancer, and RCC, making it a key target for cancer therapy [130]. The gene discussed is PIK3CG; the disease is renal cell carcinoma.